You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Congresses and Publications

Congress Materials

Access English-language abstracts, posters, and presentations presented at the following congresses

July 2025

International Health Economics Association (IHEA)

International Health Economics Association (IHEA)

July 2025 (Bali, Indonesia)
July 2025

Pan Pacific Leukemia Conference (PPLC)

June 2025

European Society for Medical Oncology Gastrointestinal Cancers Congress (ESMO-GI)

European Society for Medical Oncology Gastrointestinal Cancers Congress (ESMO-GI)

June 2025 (Barcelona, Spain)
June 2025

International Conference on Malignant Lymphoma (ICML)

International Conference on Malignant Lymphoma (ICML)

June 2025 (Lugano, Switzerland)

Abstracts

A meta-analysis investigating response rates of continuous BTKi monotherapies in the treatment of B-cell lymphomas A multi-country analysis of the cost of managing adverse events in chronic lymphocytic leukemia A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve (TN) chronic lymphocytic leukemia (CLL) AdvanTIG-101: A phase 1b/2 study of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) or rituximab in relapsed/refractory diffuse large B-cell lymphoma Adverse events of interest with zanubrutinib vs fixed-duration combination of venetoclax + obinutuzumab in treatment-naive chronic lymphocytic leukemia BGB-11417-302, a phase 3, randomized, double-blind study of sonrotoclax (BGB-11417) + zanubrutinib vs placebo + zanubrutinib in relapsed/refractory mantle cell lymphoma Combination of zanubrutinib + venetoclax for treatment-naive CLL/SLL: results in SEQUOIA arm D Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) + zanubrutinib induces high rate of complete remission in relapsed/refractory mantle cell lymphoma Comparative efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naive (TN) chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia Final analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Final independent review data supports sustained benefit of zanubrutinib over ibrutinib in patients with R/R CLL/SLL in ALPINE Preferences for treatment in first-line chronic lymphocytic leukemia: A multi-criteria decision analysis in Italy Prospective patient preference study for chronic lymphocytic leukemia (CLL) treatment attributes impacting patient shared-decision making Real-world burden of disease (BoD), treatment (tx) patterns, and outcomes in patients with mantle cell lymphoma (MCL) Real-world comparative effectiveness of first-line Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia Risk of hypertension in patients diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors: a real-world study SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Sonrotoclax (BGB-11417), a novel BCL2 inhibitor, plus zanubrutinib (zanu) demonstrates deep and durable responses in relapsed/refractory CLL/SLL: updated phase 1 results Tislelizumab, an anti-PD-1 antibody, in patients with relapsed/refractory classical Hodgkin lymphoma: final analysis from the LYSA phase 2 TIRHOL study BGB-A317-210 Treatment preferences of patients, caregivers, and physicians in follicular lymphoma: a global discrete-choice experiment study Updated efficacy & safety of BTK degrader BGB-16673 in patients (pts) with relapsed/refractory Waldenström macroglobulinemia (R/R WM): ongoing phase 1 CaDAnCe-101 results Updated efficacy/safety of Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory (R/R) indolent NHL: ongoing phase 1 CaDAnCe-101 results Updated efficacy/safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in relapsed/refractory (R/R) CLL/SLL: results from the ongoing phase 1 CaDAnCe-101 study Updated interim results of sonrotoclax + dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma (R/R MM): an all-oral treatment
June 2025

European Hematology Association (EHA)

European Hematology Association (EHA)

June 2025 (Milan, Italy)

Posters

AdvanTIG-101: a Phase 1b/2 study of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) or rituximab in relapsed/refractory diffuse large b-cell lymphoma BTK-A428D is a cross-resistant mutation to both BTK inhibitors and degraders Combination of zanubrutinib + venetoclax for treatment-naive CLL/SLL: results in SEQUOIA arm D Comparative Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC) Final analysis of a Phase 1 study of zanubrutinib (Zanu) plus lenalidomide (Len) in patients with relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL) Primary analysis results of novel bcl2 inhibitor sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory b-cell malignancies Real-World comparative effectiveness of first-line bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia Real-World treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: age-related disparity Real-World zanubrutinib treatment paterns in mantle cell lymphoma among US community oncology patients with prior bruton tyrosine kinase inhibitor therapy Real-world burden of disease, treatment paterns and outcomes in patients with mantle cell lymphoma (MCL) Risk of hypertension in patients newly diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and treated with covalent bruton tyrosine kinase inhibitors (cBTKi): A Real-World study SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Serious infections in patients with CLL/SLL treated with combination venetoclax and obinutuzumab compared with those treated with zanubrutinib: a real-world study Sonrotoclax monotherapy for treatment of patients with relapsed/refractory CLL: data from an ongoing Phase 1/1B study (BGB-11417-101) Updated interim results of sonrotoclax + dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma: an all-oral treatment Updated safety & antileukemic activity data of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia unfit for intensive chemotherapy Updated safety and antileukemic activity data for sonrotoclax (BGB-11417), a potent and selective bcl2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Updated safety and efficacy results of a Phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory waldenström macroglobulinemia Zanubrutinib (zanu) demonstrates robust efficacy in both TP53 wildtype and mutated B cancer cells in preclinical studies

Abstracts

Adverse events of interest with zanubrutinib vs fixed-duration combination of venetoclax + obinutuzumab in treatment-naive chronic lymphocytic leukemia A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve (TN) chronic lymphocytic leukemia (CLL) A qualitative study to explore the patient experience of continuous covalent bruton tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL): study methodology AdvanTIG-101: a Phase 1b/2 study of ociperlimab (anti-TIGIT) plus tislelizumab (anti-PD-1) or rituximab in relapsed/refractory diffuse large b-cell lymphoma BGB-11417-302, a Phase 3, randomized, double-blind study of sonrotoclax (BGB-11417) + zanubrutinib vs placebo + zanubrutinib in patients with relapsed or refractory mantle cell lymphoma BTK-A428D is a cross-resistant mutation to both BTK inhibitors and degraders Combination of zanubrutinib + venetoclax for treatment-naive CLL/SLL: results in SEQUOIA arm D Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib induces high rate of complete remission for patients with relapsed/refractory mantle cell lymphoma Comparative Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC) Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naive chronic lymphocytic leukemia: a matching-adjusted indirect comparison Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia Final analysis of a Phase 1 study of zanubrutinib (Zanu) plus lenalidomide (Len) in patients with relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL) Final independent review data supports sustained benefit of zanubrutinib over ibrutinib in patients with R/R CLL/SLL in ALPINE Preferences for treatment in first-line chronic lymphocytic leukemia: a multi-criteria decision analysis in Italy Primary analysis results of novel bcl2 inhibitor sonrotoclax (BGB-11417) monotherapy in patients with relapsed/refractory b-cell malignancies Real-World Zanubrutinib Treatment Paterns in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Among US Community Oncology Patients With Prior Acalabrutinib Therapy Real-World bruton tyrosine kinase inhibitor use and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma Real-World comparative effectiveness of first-line bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia Real-World treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: age-related disparity Real-World zanubrutinib treatment paterns in mantle cell lymphoma among US community oncology patients with prior bruton tyrosine kinase inhibitor therapy Real-world burden of disease, treatment paterns and outcomes in patients with mantle cell lymphoma (MCL) Risk of hypertension in patients newly diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and treated with covalent bruton tyrosine kinase inhibitors (cBTKi): A Real-World study SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Serious infections in patients with CLL/SLL treated with combination venetoclax and obinutuzumab compared with those treated with zanubrutinib: a real-world study Sonrotoclax monotherapy for treatment of patients with relapsed/refractory CLL: data from an ongoing Phase 1/1B study (BGB-11417-101) Updated efficacy & safety of the bruton tyrosine kinase (btk) degrader BGB-16673 in patients with relapsed/refractory waldenström macroglobulinemia (WM): ongoing phase (PH) 1 CADANCE-101 study results Updated efficacy and safety of the bruton tyrosine kinase (BTK) degrader BGB-16673 in patients (PTS) with relapsed or refractory (R/R) CLL/SLL: results from the ongoing Phase (PH) 1 CADANCE-101 study Updated interim results of sonrotoclax + dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma: an all-oral treatment Updated results from the Phase 1 study of sonrotoclax (bgb-11417), a novel BCL2 inhibitor, in combination with zanubrutinib for relapsed/refractory CLL/SLL demonstrate deep and durable responses Updated safety & antileukemic activity data of sonrotoclax (BGB-11417), a potent and selective BCL2 inhibitor, in treatment-naive patients with acute myeloid leukemia unfit for intensive chemotherapy Updated safety and antileukemic activity data for sonrotoclax (BGB-11417), a potent and selective bcl2 inhibitor, in patients with relapsed/refractory acute myeloid leukemia Updated safety and efficacy results of a Phase 1 study of the novel BCL2 inhibitor sonrotoclax (BGB-11417) for relapsed/refractory waldenström macroglobulinemia Zanubrutinib (zanu) demonstrates robust efficacy in both TP53 wildtype and mutated B cancer cells in preclinical studies
May 2025

American Society of Clinical Oncology (ASCO)

American Society of Clinical Oncology (ASCO)

May 2025 (Chicago, Illinois, USA)

Abstracts

A first-in-human, phase 1a/b, dose-escalation/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+/HER2- breast cancer and other advanced solid tumors: first disclosure of clinical data A network meta-analysis (NMA) of efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced NSCLC, HNSCC or NPC A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies Adverse events of interest (AEIs) with zanubrutinib vs fixed-duration combination of venetoclax + obinutuzumab in treatment-naïve chronic lymphocytic leukemia (CLL) Combination of zanubrutinib and venetoclax for treatment-naïve CLL/SLL: results in SEQUOIA arm D Comparative efficacy of zanubrutinib versus fixed-duration acalabrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Comparing real-world treatment patterns and outcomes of zanubrutinib and acalabrutinib in CLL/SLL at University of California academic health centers Efficacy of continuous zanubrutinib vs fixed-duration venetoclax in combination with obinutuzumab in treatment-naïve chronic lymphocytic leukemia (CLL): a matching-adjusted indirect comparison (MAIC) Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia (CLL) Final analysis of a multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab in combination with fruquintinib in patients with selected solid tumors First-in-human study of BG-C9074: Preliminary results of the dose-escalation phase Lung cancer enrollment of demographic subgroups in US clinical trial sites Real-world Bruton tyrosine kinase inhibitor (BTKi) use and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) Real-world comparative effectiveness of first-line Bruton tyrosine kinase inhibitors (BTKis) in patients with chronic lymphocytic leukemia Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitor (BTKi) in chronic lymphocytic leukemia (CLL): age-related disparity Real-world zanubrutinib treatment patterns in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) among US community oncology patients with prior acalabrutinib therapy Real-world zanubrutinib treatment patterns in mantle cell lymphoma (MCL) among US community oncology patients with prior Bruton tyrosine kinase inhibitor (BTKi) therapy Risk of hypertension in patients newly diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and treated with covalent Bruton tyrosine kinase inhibitors (cBTKi): a real-world study SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma Serious infections in patients with CLL/SLL treated with combination venetoclax and obinutuzumab compared with those treated with zanubrutinib: a real-world study Tislelizumab plus chemotherapy/chemoradiotherapy as positron emission tomography (PET)-guided neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis Treatment preferences of patients, caregivers, and physicians in follicular lymphoma (FL): a global-discrete experience (DCE) study

Most Recent Publications

Banner image with blue and red molecule Your ability to access these articles may depend on your or your institution's subscriptions to the journals.

Search Publications and Congress Materials

This website houses a database of publications and congress materials from medical congresses around the world. Use our search engine below to access information pertinent to your search needs.

BeOne Medicines I GmbH maintains the site for your personal information, education, and communication. Please feel free to browse the site. You may not, however, distribute, modify, transmit, reuse, repost or use the content of the site for public or commercial purposes, including the text and images, without BeOne Medicines' written permission.  
 
This is an online medical resource for scientific and clinical information. BeOne Medicines makes no representation that the information in this site is appropriate for every country or region. If you choose to access this site, you are responsible for compliance with applicable local laws.